EDIT Editas Medicine, Inc.
Price Chart
Executive Summary
Editas Medicine priced a dilutive underwritten public offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares (or pre-funded warrants in lieu thereof) at a combined public offering price of $2.25 per unit. Gross proceeds are approximately $125 million ($117 million net), with potential additional proceeds of ~$194 million if all warrants are exercised. The company estimates the net proceeds, together with existing cash, will fund operations into the second half of 2028.
Actionable Insight
This is a highly dilutive capital raise for a pre-revenue biotech with a $270M market cap — the 55.6M new shares represent a massive increase in share count. The $3.50 warrant strike is well above the $2.25 offering price, creating a long-term overhang. Monitor the stock for continued selling pressure as the offering settles. The cash runway extension into H2 2028 provides a buffer for EDIT-401 clinical development, but near-term dilution is the dominant factor.
Key Facts
- 55,555,556 shares of common stock and 55,555,556 accompanying common stock warrants priced at $2.25 per unit
- Combined public offering price of $2.25 per share and warrant
- Underwriters purchase price of $2.1150 per unit
- Estimated net proceeds of approximately $117.0 million after underwriting discounts and estimated expenses
- Warrant exercise price of $3.50 per share (or $3.4999 if exercised for pre-funded warrants)
- Warrants expire on the earlier of 30 days after positive Phase 1 EDIT-401 data announcement or three years from issuance
- If all warrants exercised in cash, additional gross proceeds of approximately $194.4 million
- Net proceeds plus existing cash expected to fund operations into the second half of 2028
- Offering expected to close on or about May 27, 2026
- Cantor Fitzgerald & Co. and Wells Fargo Securities acting as joint book-running managers
Financial Impact
Gross proceeds of $125 million from the offering; net proceeds of approximately $117 million after underwriting discounts and estimated expenses. Potential additional proceeds of up to ~$194 million if all warrants are exercised.
Risk Factors
- Massive dilution: 55.6M new shares represent a substantial increase over the current outstanding share count for a $270M market cap company
- Warrant overhang: 55.6M additional shares exercisable at $3.50 could further dilute if the stock appreciates
- Pre-revenue biotech with no approved products — clinical trial risk for EDIT-401 remains high
- Cash burn rate may accelerate if clinical development requires more capital than anticipated
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066317 |
| Document: tm2615565d3_ex1-1.htm | 0001104659-26-066317 |
| Document: tm2615565d3_8k.htm | 0001104659-26-066317 |
| Document: tm2615565d3_ex5-1.htm | 0001104659-26-066317 |
| Document: tm2615565d3_ex99-1.htm | 0001104659-26-066317 |
| Document: 0001104659-26-066317-index-headers.html | 0001104659-26-066317 |
| Document: 0001104659-26-066317-index.html | 0001104659-26-066317 |
| Document: 0001104659-26-066317.txt | 0001104659-26-066317 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $2.49 awaiting T+5 | awaiting T+5 | — | $2.50 (+0.60%) |
|
May 26, 2026
17d ago
|
424B5
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
17d ago
|
8-K
| $3.57 $2.82 | ▲ +21.01% | ▲ +22.22% | $2.50 (+29.97%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
8-K
| $3.08 $3.34 | ▲ +8.44% | ▲ +7.36% | $2.50 (−18.83%) |
|
May 26, 2026
18d ago
|
424B5
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $3.34 | ▼ −8.44% | ▼ −7.36% | $2.50 (+18.83%) |
|
May 26, 2026
18d ago
|
Press Release
| $3.08 $2.82 | ▼ −8.44% | ▼ −9.65% | $2.50 (−18.83%) |
|
May 14, 2026
4w ago
|
8-K
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
|
May 14, 2026
4w ago
|
Press Release
| $2.85 $2.67 | ▼ −6.32% | ▼ −5.60% | $2.50 (−12.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access